These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 23971933)

  • 21. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.
    Lacombe K; Boyd A; Lavocat F; Pichoud C; Gozlan J; Miailhes P; Lascoux-Combe C; Vernet G; Girard PM; Zoulim F
    Hepatology; 2013 Sep; 58(3):912-22. PubMed ID: 23468093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
    Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
    J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
    Pipili C; Cholongitas E; Papatheodoridis G
    Aliment Pharmacol Ther; 2014 Jan; 39(1):35-46. PubMed ID: 24299322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
    Qi X; Wang J; Chen L; Huang Y; Qin Y; Mao R; Zhang J
    Medicine (Baltimore); 2015 Apr; 94(15):e646. PubMed ID: 25881837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
    Li X; Liu Y; Xin S; Ji D; You S; Hu J; Zhao J; Wu J; Liao H; Zhang XX; Xu D
    Microb Drug Resist; 2017 Jun; 23(4):516-522. PubMed ID: 27792585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of antiviral-resistant chronic hepatitis B virus infection].
    Yim HJ
    Korean J Gastroenterol; 2008 Jun; 51(6):346-59. PubMed ID: 18604136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases].
    Ergünay K; Kahramanoğlu Aksoy E; Simşek H; Alp A; Sener B; Tatar G; Us D; Hasçelik G
    Mikrobiyol Bul; 2013 Oct; 47(4):628-35. PubMed ID: 24237431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
    Mello FC; Fernandes CA; Gomes Sde A
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):317-25. PubMed ID: 22510826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.